Nektar and Bristol-Myers Squibb announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials (source: Yahoo Finance).
The 19% jump is making Nektar trading around its fair value. Likely, profit-taking will take place in the next sessions. I'm expecting the stock price to consolidate around $23 level.
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.
Don't forget to support this idea, if you liked it, and to follow me here on TradingView.
Investing Fellow
The 19% jump is making Nektar trading around its fair value. Likely, profit-taking will take place in the next sessions. I'm expecting the stock price to consolidate around $23 level.
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.
Don't forget to support this idea, if you liked it, and to follow me here on TradingView.
Investing Fellow
Transakcja zamknięta: osiągnięto wyznaczony cel